CONFERENCE COVERAGE SERIES
Dominantly Inherited Alzheimer Network 2012
St. Louis, Missouri
27 September 2012
Thought you just got an earful on solanezumab? A day after its Phase 3 data presentation, this therapeutic antibody is in the news again, this time as one of three investigational therapies the DIAN Trials Unit has chosen from among 15 nominations. Starting in 2012, DIAN will test solanezumab, Roche's monoclonal antibody gantenerumab, and probably also Lilly's BACE-1 inhibitor in the network's first clinical trial. The trial will enroll 160 carriers and 80 non-carriers from among current DIAN participants, who get first dibs,and additional people who express interest through DIAN's extended registry. This announcement comes two weeks after DIAN scientists, participants, and other stakeholders met at DIAN's hub at Washington University in St. Louis, Missouri, to exchange scientific news on their ambitious joint project.
DIAN Trial Picks Gantenerumab, Solanezumab, Maybe BACE Inhibitor
Today, scientists of DIAN's Trials Unit announced their drug choices for trials to try to prevent dementia in people who have inherited autosomal-dominant mutations...
Expanding the Network, DIAN Starts Showing Longitudinal Data
When the Dominantly Inherited Alzheimer Network gathered at the its hub at Washington University, St. Louis, Missouri, researchers exchanged new science on ARIA...
Data in Disguise: As Results Roll In, DIAN Works to Guard Privacy
DIAN leaders wrestled with the sensitive issue of genetic confidentiality when reporting data in scientific publications...
Families Fight Back As Disease Claws at Next Generation
Families participating in the DIAN made an impassioned case for pressing on with clinical trials at two recent gatherings of the network...